- Routine prophylactic treatment
- Peri-operative management of surgical bleeding
)
Corifact®
Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.
Product Information
CORIFACT is a Factor XIII concentrate indicated for adult and pediatric patients with congenital Factor XIII deficiency for:
Do not use in patients with known anaphylactic or severe systemic reactions to human plasma-derived products.
- 40 International Units (IU) per kg body weight.
- Adjust dose ±5 IU per kg to maintain 5% to 20% trough level of FXIII activity.
- For routine prophylaxis, administer every 28 days
| FXIII Activity Trough Level (%) | Dosage Change | |
|---|---|---|
| One trough level of <5% | Increase by 5 IU per kg | |
| Trough level of 5% to 20% | No Change | |
| Two trough levels of >20% | Decrease by 5 IU per kg | |
| One trough level of >25% | Decrease by 5 IU per kg | |
- For peri-operative management of surgical bleeding, individualize dose based on the patient’s FXIII activity level, type of surgery, and clinical response
- Following are dose adjustment examples for peri-operative management in reference to the patient’s last prophylactic dose
| Time Since Last Dose | Dose |
|---|---|
| Within 7 days | Additional dose may not be needed |
| 8 - 21 days | Additional partial or full dose may be needed based on FXIII activity level |
| 21 - 28 days | Full prophylactic dose |
- For intravenous use only
- Administer at a rate not exceeding 4 mL per minute
- Each vial contains 1000-1600 units of lyophilized powder for reconstitution. The actual FXIII potency for each lot is printed on the vial label and carton.
- The potency expressed in International Units is determined using the Berichrom activity assay, referenced to the current International Standard for Blood Coagulation Factor XIII, Plasma
